Company news
ImmuPharma plc news in 2022
ImmuPharma plc's news releases, calls and decks from 2022, newest first.
Grant of Options
December 22, 2022
Company Secretary Change
October 7, 2022
Interim Results or the 6mths Ended 30 June 2022
September 30, 2022
Written Response received from the FDA
September 14, 2022
Exercise of Options
September 7, 2022
FDA response for Type C Meeting - update
August 31, 2022
TR-1 Notification of major holdings
August 17, 2022
Total Voting Rights
August 16, 2022
Result of Broker Option / PDMR Dealings
August 11, 2022
Investor Presentation - Investor Meet Company
August 4, 2022
Subscription/Placing to raise £1.1m; Broker Option
August 3, 2022
Initiation of Research
July 11, 2022
Confirmed FDA response date for Type C Meeting
July 7, 2022
Admission of new ordinary shares of £0.01
June 28, 2022
Update on Lupuzor
June 27, 2022
Finals results for y/e 31 December 2021
May 25, 2022
UPDATE on LUPUZORT PROGRESS to PHASE 3 with AVION
May 4, 2022
UPDATE on P140 (LUPUZORT) clinical progress
April 13, 2022
Lupuzor update
February 7, 2022